Yixin Bao
Overview
Yixin is an associate at Crowell & Moring’s Chicago office, focusing on intellectual property, including patents, trademarks, and copyrights. She works with clients globally, gaining insight into their distinct business needs and concerns.
Yixin has supported partners and counsels in complex patent litigation, helping to develop strategies to protect and enforce clients' patent rights across various industries. She has also managed patent applications, ensuring clients' innovations are protected through drafting responses to office actions before the U.S. Patent and Trademark Office. Yixin works with clients both in the U.S. and internationally, addressing the needs of a global clientele. Additionally, she has expanded her knowledge to include trademark prosecution, searching, portfolio management, and litigation.
Career & Education
- Student Associate, University of Washington Entrepreneurial Law Clinic, 2023–2024
- Editorial Staff, Washington Journal of Law, Technology, & Arts, 2023–2024
- Judicial Extern to the Honorable Justice Mary Yu at the Washington Supreme Court, 2023
- University of Illinois at Urbana Champaign, B.S., Mathematics, Statistics, and Political Science, 2019
- University of Washington, J.D., 2024
- Illinois
- Mandarin
Yixin's Insights
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
Yixin's Insights
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
